VORETIGENE NEPARVOVEC (Luxturna®)

Clinical Indication

Vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations

Comments

Not yet reviewed

Date of classification

February 2020

Review date

February 2020

Black

Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.

All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry.